

Pneumococcal Conjugate Vaccines

Vaccine Description	<ul style="list-style-type: none"> • Brand: VAXNEUVANCE™ (PCV15) • Brand: Prevnar 20™ (PCV20) • Inactivated protein-conjugated vaccines • Contain diphtheria protein and aluminum phosphate • See package inserts for more information and full lists of vaccine components
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: IM
Indications	<ul style="list-style-type: none"> • All persons 2 – 59 months of age • Persons 6 – 18 years of age with certain risk factors: <ul style="list-style-type: none"> ◦ Cerebrospinal fluid (CSF) leak ◦ Chronic heart disease (especially cyanotic congenital heart disease and cardiac failure) ◦ Chronic kidney disease (excluding maintenance dialysis and nephrotic syndrome, which are included in immunocompromising conditions) ◦ Chronic liver disease ◦ Chronic lung disease (including moderate persistent or severe persistent asthma) ◦ Cochlear implant ◦ Diabetes mellitus ◦ Immunocompromising conditions (e.g., on maintenance dialysis or with nephrotic syndrome; congenital or acquired asplenia or splenic dysfunction; congenital or acquired immunodeficiencies; diseases and conditions treated with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and solid organ transplant; HIV infection; and sickle cell disease or other hemoglobinopathies).

Pneumococcal Conjugate Vaccines (Continued)

Administration Schedules	<ul style="list-style-type: none"> • VAXNEUVANCE™ (PCV15) <ul style="list-style-type: none"> ◦ Age 2 - 59 months: four routine doses at ages 2, 4, 6, and 12 - 15 months ◦ An additional dose may be indicated at ages 6 - 18 years. • Prenar 20™ (PCV20) <ul style="list-style-type: none"> ◦ Age 2 - 59 months: four routine doses at ages 2, 4, 6, and 12 - 15 months ◦ Doses may be indicated at ages 2 - 18 years for persons who only received PCV13 or PCV15. • See Pneumococcal Vaccine Schedule tables on the following pages for specific dosing and intervals.
Contraindications	<ul style="list-style-type: none"> • Serious reaction (e.g., anaphylaxis) after a previous dose of pneumococcal vaccine, to any vaccine containing diphtheria toxoid, or to a vaccine component (including yeast)
Precautions	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever.
Special Considerations	<ul style="list-style-type: none"> • Pregnancy: provider may consider giving if increased risk for infection or poor outcome from infection. • For individuals with anatomic or functional asplenia and/or HIV: PCV vaccines and Menactra (MenACYW-D) should not be given concomitantly. Administer Menactra \geq 4 weeks after completion of all PCV doses.
<p>VIS: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/pcv.html MMWR: https://www.cdc.gov/mmwr/volumes/72/wr/mm7239a5.htm Standing orders: www.health.mil/standingorders Additional education may be found at www.health.mil/pneumococcal</p>	

Pneumococcal Polysaccharide Vaccine

Vaccine Description	<ul style="list-style-type: none"> • Brand: PNEUMOVAX 23® (PPSV23) • Inactivated bacterial polysaccharide vaccine • Contains phenol • See package insert for more information and a full list of vaccine components
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: IM or SC
Indications	<ul style="list-style-type: none"> • Persons 2 – 18 years of age with certain risk factors (see Pneumococcal Conjugate Vaccines – Pediatric above) who previously received PCV13 or PCV15. • Not indicated for individuals who previously received PCV20.
Administration Schedule	<ul style="list-style-type: none"> • One or two doses after receipt of PCV13 or PCV15 <ul style="list-style-type: none"> ◦ When PCV20 is used, no subsequent PPSV23 is recommended. • See Pneumococcal Vaccine Schedule table on the following page for specific dosing and intervals.
Contraindications	<ul style="list-style-type: none"> • Serious reaction (e.g., anaphylaxis) after a previous dose of pneumococcal vaccine or to a vaccine component.
Precautions	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever. • Persons with severely compromised cardiovascular or pulmonary function in whom a systemic reaction would pose a significant risk.
Special Considerations	<ul style="list-style-type: none"> • Pregnancy: provider may consider giving if increased risk for infection or poor outcomes from infection.
<p>VIS: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/ppv.html MMWR: https://www.cdc.gov/mmwr/volumes/72/wr/mm7239a5.htm Standing orders: www.health.mil/standingorders Additional education may be found at www.health.mil/pneumococcal</p>	

Pneumococcal Vaccine Schedule (Pediatric)

Do not give pneumococcal conjugate (PCV) and pneumococcal polysaccharide (PPSV) vaccine at the same visit.

Age 2 – 59 months (all individuals)

Routine schedule:

PCV15 or
PCV20

PCV15 or
PCV20

PCV15 or
PCV20

PCV15 or
PCV20

Age: 2 months

4 months

6 months


12 – 15 months

Age 2 – 18 years with any risk condition* and completed all recommended routine PCV doses before age 6 years:


a. Recommended routine PCV doses included ≥ 1 dose PCV20:

No additional doses of **any** pneumococcal vaccine indicated until age ≥ 65 years

b. Recommended routine PCV doses included PCV13 or PCV15 (no PCV20):



Age 6 – 18 years with any risk condition* and have not received PCV13, PCV15, or PCV20¹:



If PCV15 and PPSV23 are used instead of PCV20 for children with an immunocompromising condition*, either PCV20 or a second PPSV23 dose is recommended 5 years later (see additional dose after PPSV23 in section b above).

- Complete all recommended PCV doses before giving PPSV23
- No more than two doses of PPSV23 recommended before age 65 years